Recent progress in modeling and treating diabetes using stem cell-derived islets

Stem Cells Transl Med. 2024 Oct 10;13(10):949-958. doi: 10.1093/stcltm/szae059.

Abstract

Stem cell-derived islets (SC-islets) offer the potential to be an unlimited source of cells for disease modeling and the treatment of diabetes. SC-islets can be genetically modified, treated with chemical compounds, or differentiated from patient derived stem cells to model diabetes. These models provide insights into disease pathogenesis and vulnerabilities that may be targeted to provide treatment. SC-islets themselves are also being investigated as a cell therapy for diabetes. However, the transplantation process is imperfect; side effects from immunosuppressant use have reduced SC-islet therapeutic potential. Alternative methods to this include encapsulation, use of immunomodulating molecules, and genetic modification of SC-islets. This review covers recent advances using SC-islets to understand different diabetes pathologies and as a cell therapy.

Keywords: cellular therapy; diabetes; diabetes modeling; differentiation; immunosuppression; pancreatic differentiation; pluripotent stem cells; transplantation.

Publication types

  • Review

MeSH terms

  • Animals
  • Cell Differentiation
  • Diabetes Mellitus / therapy
  • Humans
  • Islets of Langerhans Transplantation* / methods
  • Islets of Langerhans* / cytology
  • Islets of Langerhans* / metabolism
  • Stem Cell Transplantation / methods
  • Stem Cells / cytology